Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2529]

ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer

ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate...

Dermatologists and oncologists call for overhaul of widely used cancer side-effect grading system

Dermatologists and oncologists call for overhaul of widely used cancer side-effect grading system

Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy

Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination...

Low vitamin D levels linked to more pain after breast cancer surgery

Low vitamin D levels linked to more pain after breast cancer surgery

Newly designed peptides suggest safer immunotherapies are within reach

Newly designed peptides suggest safer immunotherapies are within reach

Recognising and managing IEC-HS: A life-threatening complication of CAR-T therapy

Recognising and managing IEC-HS: A life-threatening complication of CAR-T therapy

Screening modestly reduces prostate cancer deaths

Screening modestly reduces prostate cancer deaths

How immune-related adverse events differ in elderly gastrointestinal vs. lung cancer patients

How immune-related adverse events differ in elderly gastrointestinal vs. lung cancer patients

RAS inhibitor daraxonrasib demonstrates initial anti-tumour activity in pancreatic cancer

RAS inhibitor daraxonrasib demonstrates initial anti-tumour activity in pancreatic cancer

RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer phase 1/2 study

RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer phase 1/2 study

More from ecancer